Literature DB >> 15308879

Hypertension, the metabolic syndrome, and the risk of developing diabetes: is it time to change the guidelines?

Michael A Weber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15308879      PMCID： PMC8109305          DOI： 10.1111/j.1524-6175.2004.03751.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  15 in total

1.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

4.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

Authors:  M J Brown; C R Palmer; A Castaigne; P W de Leeuw; G Mancia; T Rosenthal; L M Ruilope
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

5.  Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group.

Authors:  S Wassertheil-Smoller; C Fann; R M Allman; H R Black; G H Camel; B Davis; K Masaki; S Pressel; R J Prineas; J Stamler; T M Vogt
Journal:  Arch Intern Med       Date:  2000-02-28

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Metabolic characteristics of hypertension: importance of positive family history.

Authors:  J M Neutel; D H Smith; W F Graettinger; R L Winer; M A Weber
Journal:  Am Heart J       Date:  1993-10       Impact factor: 4.749

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

10.  Adverse prognostic significance of new diabetes in treated hypertensive subjects.

Authors:  Paolo Verdecchia; Gianpaolo Reboldi; Fabio Angeli; Claudia Borgioni; Roberto Gattobigio; Lucia Filippucci; Silvia Norgiolini; Costanza Bracco; Carlo Porcellati
Journal:  Hypertension       Date:  2004-03-22       Impact factor: 10.190
View more
  2 in total

1.  Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome.

Authors:  Melvin R Hayden; James R Sowers
Journal:  J Am Soc Hypertens       Date:  2008-06-02

2.  Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Jackson T Wright; Sonja Harris-Haywood; Sara Pressel; Joshua Barzilay; Charles Baimbridge; Charles J Bareis; Jan N Basile; Henry R Black; Richard Dart; Alok K Gupta; Bruce P Hamilton; Paula T Einhorn; L Julian Haywood; Syed Z A Jafri; Gail T Louis; Paul K Whelton; Cranford L Scott; Debra L Simmons; Carol Stanford; Barry R Davis
Journal:  Arch Intern Med       Date:  2008-01-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.